Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT07409766
First seen Feb 21, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This early-phase study tests a new treatment called CAR-Macrophage therapy for people with advanced solid tumors that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells based on specific markers like HER2, PSMA, or FAP. The main goals are to check safety, find the best dose, and see if the treatment can shrink tumors. About 20 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, 100000, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.